Daré Bioscience (NASDAQ:DARE) Shares Pass Below 200-Day Moving Average – Time to Sell?

Daré Bioscience, Inc. (NASDAQ:DARE)’s share price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $3.55 and traded as low as $3.03. Daré Bioscience shares last traded at $3.12, with a volume of 53,089 shares traded.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Daré Bioscience in a research report on Tuesday, December 17th.

Daré Bioscience Price Performance

The firm’s 50 day simple moving average is $3.47 and its two-hundred day simple moving average is $3.55. The firm has a market capitalization of $27.14 million, a P/E ratio of -5.28 and a beta of 1.27.

Institutional Trading of Daré Bioscience

An institutional investor recently raised its position in Daré Bioscience stock. Renaissance Technologies LLC lifted its position in shares of Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 778,700 shares of the biotechnology company’s stock after purchasing an additional 15,800 shares during the period. Renaissance Technologies LLC owned 9.25% of Daré Bioscience worth $262,000 as of its most recent SEC filing. 6.70% of the stock is currently owned by institutional investors.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.